KDIGO has published 17 kidney disease guidelines, but traditional full-revision cycles take years and lag behind rapidly evolving therapies such as SGLT2 inhibitors and finerenone. This article describes KDIGO's transition to modular, faster guideline updates to accelerate evidence translation into cardiometabolic clinical practice.
Kidney Disease: Improving Global Outcomes (KDIGO) develops evidence-based clinical practice guidelines to improve care for people with kidney disease worldwide. KDIGO has produced 17 guidelines across kidney care, and 7 of these have been updated comprehensively at least once. Historically, guidelines were revised in their entirety when novel therapies or treatment paradigms emerged—a process requiring years to complete. To respond more dynamically to accelerated clinical trial results and drug approvals, KDIGO recently adopted a modular update approach for some guidelines.
